Welcome to our dedicated page for Evotec SEC filings (Ticker: EVO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page compiles Evotec SE (EVO) filings with the U.S. Securities and Exchange Commission, giving investors structured access to the company’s regulatory disclosures. As a foreign private issuer, Evotec files its annual report on Form 20-F and submits interim information and material updates on Form 6-K.
Recent Form 6-K submissions referenced in the company’s disclosures include reports on financial results for the first half and first nine months of 2025, adjustments to revenue guidance while confirming profit guidance, and details of a share repurchase program. Other 6-Ks transmit press releases on strategic transactions, such as the planned and then finalized agreements with Sandoz regarding the Just - Evotec Biologics Toulouse site and an indefinite license to Evotec’s continuous manufacturing platform technology.
Additional 6-K filings cover business updates on Evotec’s strategy for sustainable and profitable growth, including the renaming of its Shared R&D segment to Discovery & Preclinical Development, progress in collaborations with Bristol Myers Squibb and Bayer, and the evolution of Just - Evotec Biologics toward an asset-lighter, technology-centric model.
Through Stock Titan, users can review these SEC documents alongside AI-powered summaries that clarify key points from lengthy filings. This includes context on revenue mix, cost initiatives, strategic partnerships, and capital allocation measures such as buybacks. For deeper analysis, investors can focus on how Evotec describes its platform technologies, partnered R&D asset portfolio, and guidance for future periods within its official filings.
Evotec SE received an activist disclosure from MAK Capital, which reported beneficial ownership of 12,503,512 ordinary shares, or about 7.0% of Evotec’s outstanding shares as of March 30, 2026. MAK Fund acquired these shares in open-market purchases for approximately 72,334,719 euros, funded with working capital.
MAK has begun actively engaging Evotec’s leadership. It spoke with the Chairwoman of the Supervisory Board to advocate for strategic and governance changes aimed at enhancing long-term shareholder value. MAK asked Evotec to consider nominating Dr. Wolfgang Hofmann to the Supervisory Board and to pursue an IPO followed by a spin-out of the Just-Evotec Biologics US subsidiary. No agreements have been reached, but MAK intends to continue its engagement.
Evotec launched “Horizon”, the next phase of its multi‑year transformation, introducing a new operating model across operations, science and commercial execution. The company plans to streamline its global footprint to 10 sites and adjust its workforce by up to 800 positions over the next two years.
Structural Horizon measures are expected to deliver approximately €75 million run‑rate cost savings by the end of 2027, against total cash restructuring charges of about €100 million over 2026–2028, plus non‑cash impairments. Evotec enters 2026 with around €60 million annualized cost savings already realized in 2025.
Preliminary unaudited 2025 figures indicate group revenues of about €788 million and adjusted Group EBITDA of roughly €41 million, within prior guidance. For 2026, Evotec guides to group revenues of approximately €700–780 million and adjusted Group EBITDA of about €0–40 million.
The Just – Evotec Biologics segment is expected to post around €259 million revenues, up 40% year on year, and about €53 million adjusted EBITDA, while the Discovery & Preclinical Development segment is expected at roughly €529 million revenues, down 13%, with adjusted EBITDA of about -€12 million.
For 2026–2030, Evotec’s framework targets group revenues above €1 billion (8–12% CAGR) and an adjusted EBITDA margin reaching 20% by 2028 and exceeding that level by 2030.
Novo Holdings A/S now reports no ownership in Evotec SE. In this amended Schedule 13G/A, the Danish investment firm states it beneficially owns 0 ordinary shares of Evotec SE, representing 0.0% of the class, as of 12/31/2025.
The filing shows Novo Holdings has no sole or shared voting power and no sole or shared dispositive power over any Evotec shares. It confirms that Novo Holdings’ holdings are now 5 percent or less of the class, meaning it is no longer a significant beneficial owner under U.S. disclosure rules.
Evotec SE received a Schedule 13G filing from investment entities associated with MAK Capital, disclosing a significant passive ownership position. MAK Capital Fund LP, MAK Capital One L.L.C., and Michael A. Kaufman together report beneficial ownership of 9,386,434 Ordinary Shares, representing 5.3% of Evotec’s Ordinary Shares outstanding as of January 9, 2026, based on the issuer’s website disclosure of 177,778,907 shares. The reporting persons indicate they hold shared power to vote and dispose of these shares and certify that the securities were not acquired and are not held for the purpose of changing or influencing control of Evotec SE.
Evotec SE filed a Form 6-K noting that on January 16, 2026 it submitted several Notifications of Major Holdings to the German financial regulator, Bundesanstalt für Finanzdienstleistungsaufsicht. These notifications, which disclose significant shareholdings under German law, are attached as Exhibits 99.1, 99.2 and 99.3. Exhibit 99.1 and 99.2 relate to notifications identified with “GS” dated January 13, 2026 and January 9, 2026, respectively, and Exhibit 99.3 relates to a notification identified with “MAK” dated January 9, 2026. The report is signed on behalf of Evotec SE by Chief Executive Officer Christian Wojczewski.
Evotec SE filed a Form 6-K as a foreign private issuer to inform investors that it submitted two Notifications of Major Holdings to the German financial regulator Bundesanstalt für Finanzdienstleistungsaufsicht.
These notifications, dated January 13, 2026 (Exhibit 99.1, MAK) and January 12, 2026 (Exhibit 99.2, Triton), are attached as exhibits to the report.
Evotec SE reported that its Seattle-based subsidiary, Just – Evotec Biologics, has received a new grant from the Gates Foundation to support global access to biotherapeutics. The funding will use the company’s AI-driven J.MD™ molecular design service, part of its J.DESIGN™ platform, to improve the developability of monoclonal antibodies so they can be manufactured more efficiently and at lower cost for low- and middle-income countries.
The grant will fund 10 new J.MD™ projects over the next three years, targeting multiple global health disease indications and building on work since 2014 that has included cGMP manufacturing campaigns for RSV, malaria, and HIV antibodies. Evotec also notes that it submitted a Notification of Major Holdings to the German financial regulator, attached as a separate exhibit.
Evotec SE reported that it has submitted Notifications of Major Holdings to the German financial regulator, Bundesanstalt für Finanzdienstleistungsaufsicht, in accordance with German law. These notifications, related to JPM and provided as Exhibits 99.1 and 99.2, are being shared with investors through this Form 6-K so the market is informed about significant shareholding positions.
Evotec SE filed a Form 6-K announcing that its management resolved on November 06, 2025 to implement a share repurchase program. The company states that the program is described in Exhibit 99.1, an announcement made pursuant to Article 5(1)(a) of Regulation (EU) No. 596/2014 and Article 2(1) of Delegated Regulation (EU) No. 2016/1052.
This is an administrative disclosure indicating the company’s decision to buy back shares, with specific terms set out in the accompanying exhibit.
Evotec SE furnished a report for investors summarizing that it has released its financial results and business updates for the first nine months of 2025. The company states that these details are contained in a press release attached as Exhibit 99.1 to this report.
The exhibit is titled “Evotec SE reports 9M 2025 results: Continued strong execution on strategic priorities,” indicating that management views its progress on key strategic goals as ongoing. The report is signed by the Chief Financial Officer, Paul Hitchin.